Shire has secured marketing authorisation from the European Commission (EC) for its Antihaemophilic Factor (Recombinant) (ADYNOVI) PEGylated drug in the European Union (EU), Iceland, Liechtenstein and Norway.

ADYNOVI is an extended half-life recombinant factor VIII (rFVIII) treatment indicated for on-demand and prophylactic use in haemophilia A patients aged 12 and above.

Based on the Antihaemophilic Factor (Recombinant) (ADVATE) treatment, the drug has been modified to ensure longer retention in blood and potentially less frequent injections when used to minimise the bleeding frequency, compared to unmodified Antihaemophilic Factor.

ADYNOVI employs PEGylation technology, which is exclusively licensed from Nektar Therapeutics, to extend the time between treatments, providing twice-a-week dosing schedule.

“The European approval of ADYNOVI is an important milestone in our continued commitment to provide new treatment options for patients living with haemophilia A.”

Shire Haematology Medical Affairs global head Dr Peter Foertig said: “The European approval of ADYNOVI is an important milestone in our continued commitment to provide new treatment options for patients living with haemophilia A.

“We believe that the twice-weekly prophylactic dosing, as well as the on-demand control of bleeding, offered by ADYNOVI will bring us closer to our goal of improving and personalising disease management for haemophilia A patients in Europe.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The EC authorisation is based on the findings from a prospective, global, multi-centre, open label, non-randomised Phase III clinical trial of subjects aged 12 to 65.

In addition, the commission also reviewed outcomes from another Phase III prospective, uncontrolled, open-label, multi-centre trial with participants aged 12 and below, and a perioperative control of haemostasis study in 15 severe haemophilia A patients receiving surgical procedures.